

Drug Discovery and Development

Molecular and Chemical Basis of


# **Cancer and Anti-Cancer Therapies**

Christian Heinis

Prof. Christian Heinis, [christian.heinis@epfl.ch](mailto:christian.heinis@epfl.ch), BCH 5305, 021 693 93 50

*What is the difference between a healthy cell  
and a cancer cell?*

# The Hallmarks of Cancer




6 (or now 10) characteristics of cancer cells

# The Hallmarks of Cancer

Article in the journal 'Cell' by Doug Hanahan and Robert Weinberg in 2000

Cited more than 10'000 times


Prof. Douglas Hanahan  
ISREC Director  
"Le Temps" of March 9, 2011  
"Comment le cancer se développe..."  
"The Hallmarks of cancer..."



*How is a healthy cell converted into a cancer cell?*

*What are the molecular processes?*

# Clonal expansion




- Cells divide and accumulate more mutations
- Variants that evade the host's defence grow faster


*Which was the first anti-cancer drug that  
became available?*

# Early history of anti-cancer drugs


- First anti-cancer drug is a **hormone** (1941): estrogen  
(administration of estrogen produced regression of metastatic prostate cancer)



- A few years later: first **alkylating agents**  
(mechlorethamine was effective against Hodgkin's lymphoma)




- 1950ies: **antimetabolites** (e.g. methotrexate, 5-fluorouracil),  
additional **alkylating agents**, **natural products**
- 1960ies: progress continues in all areas







# Alkylating agents




- Sulphur mustard was first used as chemical weapon (WWI)
- Sulphur mustard was active against animal tumours  
(but it was too toxic)
- 1946: Mechlorethamine was found active against Hodgkin's disease (lymph cancer)



# Alkylating agents




- Sulphur mustard was first used as chemical weapon (WWI)
- Sulphur mustard was active against animal tumours  
(but it was too toxic)
- 1946: Mechlorethamine was found active against Hodgkin's disease (lymph cancer)




*What is the mechanism of action of this drug?*

# Alkylating agents

## Sulfur mustard




## Nitrogen mustard




# Alkylating agents

Sulfur mustard




Nitrogen mustard




*Which molecules are good nucleophiles in a cell?*

# Alkylating agents


*Protein / amino acids?*



*DNA / nucleotides?*




G-C



T-A

# Alkylating agents: Mechanism of action


Guanine



Alkylating agents are thought to react mostly with DNA

# Alkylating agents: Mechanism of action

Guanine



Alkylating agents are thought to react mostly with DNA


## Mechanisms:

- Mutagenesis
- Strand break
- Cross-linking

→ False replication

# Alkylating agents: Mechanism of action

Guanine



Alkylating agents are thought to react mostly with DNA

## Mechanisms:


- Mutagenesis
- Strand break
- Cross-linking

→ False replication


*Why are cancer cells more affected by an alkylating agent than healthy cells?*



## Alkylating agents: Examples



melphalan



cyclophosphamide

# Antimetabolites


- Compounds that prevent the biosynthesis of **metabolites**.

# Antimetabolites

- Compounds that prevent the biosynthesis of metabolites.

Example:

tryptophan metabolism




# **Antimetabolites**

- Compounds that prevent the biosynthesis of metabolites.
- Antimetabolites bind to enzymes that are involved in the metabolite synthesis

# Antimetabolites

- Compounds that prevent the biosynthesis of metabolites.
- Antimetabolites bind to enzymes that are involved in the metabolite synthesis
- Antimetabolites have often similar structures to metabolites

Example 1:




6-mercaptopurine

# Antimetabolites

- Compounds that prevent the biosynthesis of metabolites.
- Antimetabolites bind to enzymes that are involved in the metabolite synthesis
- Antimetabolites have often similar structures to metabolites

Example 1:




6-mercaptopurine


*Which metabolite is similar to this antimetabolite ?*

# 6-mercaptopurine

Example 1:



purine



6-mercaptopurine


*Which pathway does 6-mercaptopurine inhibit?*

# De novo purine synthesis

Phosphoribosyl  
pyrophosphate

Phosphoribosyl-  
amine

PhosphoRibosylPyroPhosphate(PRPP)



PPAT

GARS

GAR Tfase

4 FGAMS

SAICARS

CAIRS

AIRS


ASL

AICAR Tfase

IMPCH

Inosine MonoPhosphate(IMP)


**PPAT** = Glutamine-PRPP-  
aminotransferase





# De novo purine synthesis

Phosphoribosyl  
pyrophosphate      Phosphoribosyl-  
amine




**PPAT** = Glutamine-PRPP-  
aminotransferase


*Why are cancer cells more affected by 6-mercaptopurine than healthy cells?*

## Example 2: Rational design of an antimetabolite of uracil (1957)

Observation: in certain tumours **uracil** was used more than **orotic acid** for nucleic acid biosynthesis



uracil




orotic acid





thymidine for  
DNA synthesis



# Conversion of uridylylate to thymidylate




# Conversion of uridylylate to thymidylate



5-fluorouracil


## A different mechanism was found



- The fluoro group prevents the full transfer of the methylene group
- Enzyme, cofactor and inhibitor form a covalent complex  
→ thymidylate synthase is irreversibly inhibited

# Antibiotics


- Original definition of '*antibiotic*' = substance produced by a micro-organism that inhibits the growth of other micro-organisms



- Many antibiotics were too toxic to be used as anti-infectious agents
- Later, some antibiotics were found to be useful as anti-cancer drugs

# Antibiotics

Example 1: **actinomycin D**




2 x pentapeptide  
lactone

3-phenoxazine-1,9-  
dicarboxylic acid

# Antibiotics

## Example 1: **actinomycin D**





2 x pentapeptide  
lactone

3-phenoxazine-1,9-  
dicarboxylic acid

*What is the mechanism of action of actinomycin D?*





# Actinomycin D





- Phenoxazine group intercalates into the double helix
- Double helix needs to unwind
- Pentapeptide-lactone groups bind into the minor grooves of the helix

*Why is the binding to the DNA toxic for the cell?*




# Actionmycin D inhibits topoisomerase II



topoisomerase II

# Antibiotics

## Example 2: anthracyclines




daunorubicin: R = H

doxorubicin: R = OH

# Antibiotics

## Example 2: anthracyclines




daunorubicin:  $\text{R} = \text{H}$

doxorubicin:  $\text{R} = \text{OH}$

*What is the mechanism of action of daunorubicin / doxorubicin?*


# Antibiotics

## Example 2: anthracyclines




daunorubicin: R = H

doxorubicin: R = OH



# Natural products

## Example 1: vinca alkaloids




vincristine




*Catharanthus Roseus*

# Effect of vincristine

Cells are stained with an anti-tubulin antibody




addition of  
vincristine




# Effect of vincristine

Cells are stained with an anti-tubulin antibody




addition of  
vincristine






# Mitotic arrest in cell cycle



Vincristine causes mitotic arrest by dissociating the  
**cytoskeleton** and the **mitotic spindle**



# Vincristine binds to tubulin



Vincristine promotes the dissociation of microtubuli


# Natural products

## Example 2: **paclitaxel (Taxol)**



Was world's leading small molecule anti-cancer agent in terms of sales.

# Inhibition of depolymerization



Taxol promotes the assembly of microtubulus and inhibits their depolymerization

→ Contrary mechanism of vinca alkaloids

# Paclitaxel was isolated from a yew tree (1971)




Bark of the Pacific yew tree *Taxus brevifolia*

- *Taxus brevifolia* is a slow growing tree and contains only small amounts of the drug → small yields
- Bristol-Myers Squibb (BMS) developed a semi-synthetic route:
  - Isolation of 10-deacetylbaccatin III from needles of *Taxus baccata* (a European yew tree)
  - Chemical transformation into paclitaxel



# Platinum complexes

Example: **cisplatin**




cisplatin

- Toxicity was discovered by accident when the effect of an electrical field on bacterial cells was tested:  
Bacterial cells formed long filaments
- Not the electrical field caused the toxicity but a complex of platinum and ammonium and chloride ions

# Platinum complexes

Example: **cisplatin**




cisplatin

- Toxicity was discovered by accident when the effect of an electrical field on bacterial cells was tested:  
Bacterial cells formed long filaments
- Not the electrical field caused the toxicity but a complex of platinum and ammonium and chloride ions

*What is the mechanism of action of cisplatin?*

# Hormones


Example: **estrogen**





# Hormones



Example: **estrogen**



*Why can hormones be used as anti-cancer drugs?*

# Hormones

- Normal and well-differentiated neoplastic cells have a number of hormone receptors




©1999 Addison Wesley Longman, Inc.

- Growth of cells can be regulated by hormones
- Many tumours are not differentiated and their growth can not be controlled by hormones

# Signal transduction inhibitors

## Example: **glivec**



imatinib (Gleevec)

## Case study:

### GLIVEC (STI571, IMATINIB), A RATIONALLY DEVELOPED, TARGETED ANTICANCER DRUG

*Renaud Capdeville, Elisabeth Buchdunger, Juerg Zimmermann and Alex Matter*



In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research. Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery programme was initiated with the aim of rationally developing targeted anticancer therapies. Here, we describe how this programme led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.

Until the early 1980s, drug discovery programmes for cancer were focused almost exclusively on DNA synthesis and cell division, and resulted in agents such as

The molecular consequence of this inter-chromosomal exchange is the creation of the *BCR-ABL* gene, which encodes a protein with elevated tyrosine-kinase activity.

# Radiotherapeutic agents

- Produce beta particles (electrons)
- Travel 3 mm and destroy cell components
- Distribute to thyroid or bone → are used to treat cancer of these organs
- Examples: sodium phosphate ( $P^{32}$ ), sodium iodide ( $I^{131}$ )



# Monoclonal antibodies

- Proteins that have a Y-shape
- Bind to foreign objects  
(bacteria, viruses etc)
- Act through inactivation or signalling
- Produced by B cells
- In blood or bodily fluids
- **Can bind with high affinity and specificity to (protein) targets**





Figure 5-22  
Lehninger Principles of Biochemistry, Fifth Edition  
© 2008 W. H. Freeman and Company

# **Antibodies with tailored binding specificities can be engineered**













# Monoclonal antibodies











Generic name	Description	Target	Approval date
Rituximab	Chimeric IgG1	CD20	1997
Trastuzumab	Humanized IgG4	HER2	1998
Gemtuzumab ozogamicin	Humanized IgG1	CD33 (immunotoxin)	2000
Alemtuzumab	Humanized IgG1	CD52	2001
Ibritumomab tiuxetan	Murine IgG1	CD20 (radiolabeled)	2002
<sup>131</sup> I-Tositumomab	Murine IgG2	CD20 (radiolabeled)	2003
Cetuximab	Chimeric IgG1	EGFR	2004
Bevacizumab	Humanized IgG1	VEGF	2004
Panitumumab	Human IgG2	EGFR	2006
Ofatumumab	Human IgG1	CD20	2009
Ipilimumab	Human IgG1	CTLA-4	2011
Denosumab	Human IgG2	RANK ligand	2010
Brentuximab vedotin	Chimeric IgG1	CD30	2011
Pertuzumab	Human IgG1	HER2	2012
Obintuzumab	Humanized and glycoengineered	CD20	2013
Trastuzumab emtansine	Humanized IgG4	HER2 (mertansine)	2013
Ramucirumab	Human IgG1	VEGFR2	2014


# 6 out of 10 top-selling drugs are mAbs


Year 2000


Drug	Sales (billion \$)	Modality
Nexium	5.3	
Lipitor	5.3	
Plavix	4.7	
Advair	3.7	
Oxycontin	3.6	
Abilify	3.5	
Singulair	3.3	
Seroquel	3.2	
Crestor	2.9	
Cymbalta	2.6	

Year 2014

Drug	Sales (billion \$)	Modality
Humira	12.5	
Solvadi	10.3	
Remicade	9.2	
Rituxan	8.7	
Enbrel	8.3	
Lantus	7.3	
Avastin	7.0	
Herceptin	6.8	
Advair	6.4	
Crestor	5.9	


small molecule 

antibody 

peptide 




# Summary of anti-cancer drug classes




- Alkylating agents


- Antimetabolites




- Natural products




- Platinum complexes



- Hormones



- Signal transduction inhibitors



- Radiotherapeutic agents

- Monoclonal antibodies